Back

PEAR1 rs12041331 polymorphisms and the risk of adverse cardiovascular outcomes in patients with acute coronary syndrome and/or percutaneous coronary intervention: a systematic review and meta-analysis

( - )
Organised by:
Congress Presentation Part of: Abstract Programme Pharmacogenetics ESC Premium Access ESC Asia with APSC & AFC 2020

About the speaker

Photo
Doctor Ke Xu

Shanghai Chest Hospital, Shanghai (China)

238 More presentations in this session

Presentation thumbnail
2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry.
Doctor D. Pol (Melbourne, AU)
Abstract
Presentation thumbnail
3D right ventricular ejection fraction and longitudinal strain are independent predictors of major adverse cardiovascular events in patients with rrhythmogenic right ventricular cardiomyopathy
Assistant Professor L. Hosseini (Bojnurd, IR)
Abstract
Presentation thumbnail
A novel pressure-regulated deployment strategy for improving the safety and efficacy of balloon-expandable transcatheter aortic valves
Doctor A. Snir (Oxford, GB)
Abstract Video
Presentation thumbnail
A novel therapeutic approach for coronary inflammation and lymphatic vessels using non-invasive low-intensity pulsed ultrasound in a porcine model with DES-induced coronary hyperconstricting responses
Doctor T. Watanabe (Sendai, JP)
Abstract Video
Presentation thumbnail
A real-world comparison of outcomes between fractional flow reserve-guided versus angiography-guided percutaneous coronary intervention
Doctor C. Wong (Sydney, AU)
Abstract

Access the full session

Session thumbnail
Abstract Programme

The Event

Event poster

ESC Asia with APSC & AFC 2020

You may be interested in
thumbnail
Congress Presentation
Genetic variations in PEAR1 are associated with progression of coronary artery disease
30 August 2024
thumbnail
Congress Presentation
2 September 2019
thumbnail
Congress Presentation
Allelic polymorphism gene ADP receptor R2RY12 T-744C in patients with HFpEF
29 June 2021
thumbnail
Congress Presentation
High plasma levels of soluble LOX-1 portends poor survival in acute coronary syndromes beyond GRACE 2.0: A multicentre prospective cohort study
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources